Phoenix Biotechnology and the Science Behind Nerium Skin Care:
From historical/anecdotal use, continuing cancer and antiviral research with Nerium oleander extracts, Nerium Biotechnology, Inc. (NBI) has identified the potential for use of Nerium Ingredients in topical skincare applications. NBI’s proprietary technologies and product formulation provides for Nerium Ingredients to be the key ingredient in each product that will be designed and formulated for a specific target. This provides NBI with the opportunity to develop for the consumer an ever expanding series of natural botanical healthcare, topical, cosmetic and OTC skin products.

Dr Robert Newman Scientific Advisor for Phoenix Biotech: San Antonio, TX:
Phoenix Biotechnology’s Chief Science Officer, Chairman of the Scientific Advisory Board, and Director. Dr. Newman obtained his M.S. and Ph.D. degrees in Pharmacology and Toxicology from the University of Connecticut and then served in postdoctoral positions at the Medical School of the University of Georgia as well as the Department of Biochemistry at the University of Vermont. He served as a faculty member at the University of Vermont Medical School for seven years and then spent a sabbatical year at Stanford University performing research on immune targeted therapy. He spent 24 years at the University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, Texas where he held the D. B. Lane Distinguished Professorship Chair. At MDACC he served as the founder and Co-Director of the Pharmaceutical Development Center and the institution's Analytical Center.

Dr Rick Matos: Phoenix Biotechnology’s Director. Dr. Matos has 32 years of experience as a pharmaceutical researcher, patent practitioner and consultant. He is an author of scientific articles and an inventor of pharmaceutical and chemical process technologies. He has integrated IP, business, R&D, regulatory, and commercialization strategies and built and managing robust large patent portfolios. Dr. Matos earned his doctorate in Bioorganic Chemistry from Texas A&M University after having completed his studies on the chemical and enzymatic synthesis of penicillin, amino acids and other natural products. He worked for The DuPont Merck Pharmaceutical Company as a Senior Research Scientist primarily on biotech large-scale process development and drug discovery in many therapeutic areas while advancing to Project Team Leader within the R&D department. After helping establish the pharmaceutical IP practice in the Dallas office of a major firm, Dr. Matos founded Innovar, L.L.C. in March of 2000.

Phoenix Biotech has developed a range of Nerium oleander extract (NOE) based products with different compositional profiles resulting from their respective methods of manufacture. Some of the products contain oleandrin and others do not.  In each case, however, the products contain components derived from plant.

The varying compositional profiles results in products exhibiting different biological activities.  Each of the products, however, is safe and effective when used as directed. This is because the products are effective even when administered at doses that are well below toxic doses. Please refer to our information on safety and therapeutic window.


Sponsor: Phoenix Biotechnology Inc. (Nerium)